Stephanie Lee, MD, MPH - Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease

Go online to PeerView.com/CJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Preventing and managing graft-versus-host disease (GVHD) remains a significant problem in the post–allogeneic hematopoietic stem cell transplant (HCT) setting. Can a wide range of unique treatment modalities, including costimulatory compounds, targeted agents, and engineered cell therapy, challenge long-standing management protocols in this setting? Find out in this activity, based on a recent live symposium, which features an overview of available and emerging therapeutic options for modern GVHD management as a means to extend the benefits of HCT and provide more effective prophylaxis and treatment. Upon completion of this activity, participants should be better able to: Summarize current safety/efficacy evidence supporting the use of novel therapeutics for prophylaxis or treatment of acute or chronic graft-versus-host-disease (GVHD) in the post-transplant setting; Develop management plans with novel and emerging therapeutics for the prophylaxis of GVHD in the post-transplant setting, based on current evidence and practice guidelines; and Integrate novel and emerging therapies into safe, personalized treatment plans for the management of acute or chronic GVHD, including novel combinatorial strategies and/or options for second-line management.